Alto Neuroscience, Inc. (ANRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.52 Million) by net assets ($151.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Alto Neuroscience, Inc. to measure how many days the company can operate on defensive assets alone.
Alto Neuroscience, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Alto Neuroscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alto Neuroscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alto Neuroscience, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Missouri Bancorp Inc
NASDAQ:SMBC
|
0.051x |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
-0.006x |
|
Ferrari Group PLC
AS:FERGR
|
0.069x |
|
Tangrenshen Group Co Ltd
SHE:002567
|
0.034x |
|
Harvia Oyj
HE:HARVIA
|
0.123x |
|
Chongqing Changan Automobile Co Ltd
SHE:200625
|
-0.065x |
|
Flexium Interconnect Inc
TW:6269
|
-0.005x |
|
Shenzhen MYS Environmental Protection & Technology Co Ltd
SHE:002303
|
0.003x |
Annual Cash Flow Conversion Efficiency for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Alto Neuroscience, Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see ANRO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $151.14 Million | $-51.77 Million | -0.343x | -9.39% |
| 2024-09-30 | $151.46 Million | $-47.42 Million | -0.313x | -167.09% |
| 2023-09-30 | $-71.67 Million | $-33.45 Million | 0.467x | -12.11% |
| 2022-09-30 | $-38.41 Million | $-20.39 Million | 0.531x | -28.46% |
| 2021-09-30 | $-12.48 Million | $-9.26 Million | 0.742x | -- |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more